Research Reports | Market Assessment
May 2016

Gram-Negative Infections | Unmet Need | HABP/VABP Gram-Negative Infections | US/EU | 2016

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including carbapenem-resistant organisms (CROs) (e.g., carbapenemase-producing Enterobacteriaceae and MDR A. baumannii and P. aeruginosa), as well as significant morbidity and mortality. Although several therapies in late-stage clinical development are active against these CROs, developers have faced difficulty in conducting HABP/VABP trials as a result of changes in and misalignment between the FDA’s and EMA’s clinical trial guidelines for this indication. Nonetheless, significant opportunity remains for antibiotic products with efficacy against drug-resistant HABP/VABP, including HABP/VABP due to CROs. Such therapies are poised to command premium prices in the GNI market.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports